Evidence map›Paper›PMID 26207141›Full record

ArticleGenome medicine2015

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.

Chulin Sha, Sharon Barrans, Matthew A Care, David Cunningham, Reuben M Tooze, Andrew Jack, David R Westhead

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. A multi-omics integrative analyses revealsFrontiers in pharmacology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Article
  14. Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chulin ShaSchool of Molecular and Cellular Biology, Garstang Building, University of Leeds, Leeds, LS2 9JT UK.
Sharon BarransHaematological, Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
Matthew A CareSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
David CunninghamRoyal Marsden Hospital, Fulham Road, London, SW3 6JJ UK.
Reuben M ToozeHaematological, Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK ; Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Andrew JackHaematological, Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
David R WestheadSchool of Molecular and Cellular Biology, Garstang Building, University of Leeds, Leeds, LS2 9JT UK.
St James's University Hospital · GBUniversity of Leeds · GBRoyal Marsden Hospital · GB

Funding

Cancer Research UK 10066Cancer Research UK 17723Medical Research Council MR/L01629X/1
6 · The paper itself

Abstract

backgroundClassifiers based on molecular criteria such as gene expression signatures have been developed to distinguish Burkitt lymphoma and diffuse large B cell lymphoma, which help to explore the intermediate cases where traditional diagnosis is difficult. Transfer of these research classifiers into a clinical setting is challenging because there are competing classifiers in the literature based on different methodology and gene sets with no clear best choice; classifiers based on one expression measurement platform may not transfer effectively to another; and, classifiers developed using fresh frozen samples may not work effectively with the commonly used and more convenient formalin fixed paraffin-embedded samples used in routine diagnosis.

methodsHere we thoroughly compared two published high profile classifiers developed on data from different Affymetrix array platforms and fresh-frozen tissue, examining their transferability and concordance. Based on this analysis, a new Burkitt and diffuse large B cell lymphoma classifier (BDC) was developed and employed on Illumina DASL data from our own paraffin-embedded samples, allowing comparison with the diagnosis made in a central haematopathology laboratory and evaluation of clinical relevance.

resultsWe show that both previous classifiers can be recapitulated using very much smaller gene sets than originally employed, and that the classification result is closely dependent on the Burkitt lymphoma criteria applied in the training set. The BDC classification on our data exhibits high agreement (~95 %) with the original diagnosis. A simple outcome comparison in the patients presenting intermediate features on conventional criteria suggests that the cases classified as Burkitt lymphoma by BDC have worse response to standard diffuse large B cell lymphoma treatment than those classified as diffuse large B cell lymphoma.

conclusionsIn this study, we comprehensively investigate two previous Burkitt lymphoma molecular classifiers, and implement a new gene expression classifier, BDC, that works effectively on paraffin-embedded samples and provides useful information for treatment decisions. The classifier is available as a free software package under the GNU public licence within the R statistical software environment through the link http://www.bioinformatics.leeds.ac.uk/labpages/softwares/ or on github https://github.com/Sharlene/BDC.

Identifiers

PMID26207141
PMCPMC4512160
OpenAlexW1502318498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.